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Abstract
Aims
Poor adherence to medication therapy among type 2 diabetes patients is a clinical chal-
lenge. We aimed to determine which factors are associated with the three phases of long-
term adherence to medication: initiation, implementation and discontinuation in a register-
based study.
Methods
Adherence to six medicine groups (metformin, sulfonylureas, acetylsalicylic acid, thiazide
diuretics, renin angiotensin system inhibitors, and statins) were analysed among 5,232
patients with type 2 diabetes at a tertiary referral hospital during 1998–2009. Rate-ratios of
initiation of treatment, recurrent gaps in supply of medication, and discontinuation of treat-
ment were analysed using Poisson regression.
Results
Poor initiation rather than poor implementation or discontinuation was the main contributor
to medication nonadherence. Polypharmacy was a risk factor for slower initiation of treat-
ment for all six medicine groups (rate ratio ranging 0.79 95%CI [0.72–0.87] to 0.89 95%CI
[0.82–0.96] per already prescribed medicine), but once patients were in treatment, polyphar-
macy was not associated with recurrence of gaps in supply of medication, and polyphar-
macy was associated with lower risk of discontinuation (rate ratio ranging 0.93 95%CI
[0.86–1.00] to 0.96 95%CI [0.93–0.99] per prescribed medicine). Other identified risk factors
for slow initiation, poor implementation, and discontinuation were diabetes duration, youn-
ger age, and Turkish/Pakistani origin.
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Discussion
This study showed that a risk factor does not necessarily have the same association with all
three elements of adherence (initiation, implementation and discontinuation), and that
efforts supporting patients introduced to more complex drug combinations should be
prioritized.
Introduction
Poor adherence to medication therapy in chronic disease is associated with a worsening of
clinical status/health[1, 2], higher risk of hospitalisation[3], risk of medicine-related hospital
admissions[4] and higher mortality risk[5]. Losing adherence has been shown to be associated
with more hospitalizations and emergency department visits[6]. Improving adherence to med-
icine could be a more efficient strategy with higher impact than any treatment itself[7].
Patients with type 2 diabetes mellitus (T2DM) are often challenged by a complex medicine
regimen targeting multiple cardiovascular disease risk factors[8, 9]. Many efforts have been
made to describe the potential predictors of adherence[10, 11][12,13]. Recent research has
focused on three different phases of adherence to medication: initiation, implementation, and
discontinuation of medication therapy[12–17], but it has primarily focused on short-term
studies with follow-up of less than three years. If and how soon patients initiate treatment after
being prescribed with medication is of interest, as well as how well patients implement the dos-
ing regimen afterwards. In chronic care, there is risk of occasionally running out of supplies of
medicine, both intentional and unintentional. Tracking events of running out of supply of
medicine, here referred to as gaps in supply of medication, and tracking the length of these
gaps provide information on implementation of the prescribed medication therapy. Finally,
tracking if patients discontinue treatment early is also of importance. Examining the associa-
tions between predictors of adherence and the three different components of adherence: in-
itiation, implementation, and discontinuation of medication therapy, may be beneficial for
patient-specific initiatives to improve adherence to medicine in diabetes.
Our aim was to estimate rates of initiation of medication therapy, the pattern of recurrent
gaps in supply of medication as a measure of implementation, and early discontinuation of
therapy for frequently used medicines among Danish patients with T2DM using a new method
and algorithm[18] for calculation of adherence to medication. Furthermore, we aimed to
investigate how condition-, therapy-, and patient-related factors are associated with the three
different phases of adherence to medication: initiation, implementation and discontinuation
among this group of T2DM patients.
Methods
Setting
The study was conducted among T2DM patients referred to the outpatient clinic at Steno Dia-
betes Center (Steno) during 1998–2009 and prescribed at least once with glucose lowering,
antihypertensive, lipid lowering or anti-coagulation therapy. Steno is a specialised diabetes ter-
tiary referral hospital for both type 1 and T2DM patients. Typically, T2DM patients with poor
glycaemic control are referred to Steno from general practice for a shorter time period in
order to improve glucose control or cardiovascular disease risk factors before they are dis-
charged back to general practice. In addition, T2DM patients with complications are referred
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to Steno for permanent diabetes treatment and control. Patients were followed from 1 January
1998 or date of first entry at Steno after 1 January 1998 to the earliest of a) 31 December 2009,
b) the latest date of referral of the patient from Steno to general practice or another specialist
unit, or c) date of death. Time spent enrolled in clinical trials at Steno, which might have
included interventions with medicine/placebo, or temporarily referred away from Steno dur-
ing follow-up was censored. Follow-up time was split in intervals of 3 months allowing the
time-varying covariates to alter with the same frequency using the value of the left endpoint of
the 3 months intervals.
Outcome
We studied four different adherence outcomes of clinical interest: (A) initiation of medica-
tion therapy, where the patient is in a state of waiting from the time the medicine is prescribed
until it is redeemed for the first time. After initiation the patient enters a state of being in treat-
ment (persistence), and the patient can only adhere to the prescribed medication if he or she
fill the prescription frequently enough to allow for a sufficient supply of the drug. If the patient
runs out of supply before refilling the next prescription, we say that a gap occurs. In this state
(B) implementation behaviour is expressed by events of alternating between being in a state
of sufficient supply of medicine and in a state of a supply gap. A supply gap is defined as less
than 51 days without medicine. If a supply gap exceeds 50 days, then we assume that (C) treat-
ment has been discontinued by the patient and he or she is no longer persistent. Details on
definition of these outcomes are described by Jensen et al.[18] based on a multistate model.
Since 1998, information on prescribed daily doses of medicine has been recorded in elec-
tronic medical records (EMR) at Steno. Data containing a unique identification number, date
of birth, year of T2DM diagnosis, referral and discharge dates to and from Steno, and informa-
tion on prescribed medicine were extracted from EMR. These data were transferred to Statis-
tics Denmark and linked to the Register of Medicinal Product Statistics (RMPS) containing
information at an individual level on prescription medicine sold at all Danish pharmacies
since 1995.
Prescribed medicine (from EMR) and prescriptions redeemed by the patients (from
RMPS), were coded according to the fifth level of the Anatomical Therapeutic Chemical
(ATC) classification system.
Covariates
Sex, country of origin, level of education, marital state and annual personal income at date of
entry at Steno were used as covariates. Five time-varying covariates were included in the analy-
ses: 1) age, 2) duration of T2DM diagnosis, 3) a Medication Complexity score (MC score): the
number of medicines prescribed at any time during follow-up as an expression of polyphar-
macy, 4) Charlson’s Comorbidity Index (CCI) expressing the degree of comorbidity at any
time during follow-up, and 5) number of times the patient has entered the state in question.
We used data from the Danish National Patient Register (NPR), which contains informa-
tion on diagnoses at Danish hospitals since 1977 for calculation of CCI; the Danish Register of
Causes of Death containing date of death; and other public registers accessible at Statistics
Denmark containing information on migration, highest level of achieved education, marital
state, income, and country of origin.
Level of education was categorised according to the International Standard Classification of
Education (ISCED 2011). Country of origin was defined by Statistics Denmark’s classification:
Danish origin, descendant or immigrant. Descendants and immigrants from the same country
were pooled.
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Current age and duration of diabetes were modelled as log-linear effects.
The CCI was calculated for each patient at entry to Steno. Registrations of diagnoses from
the NPR from up to 10 years prior to entry date were classified into the 17 comorbidity groups
in the CCI as described by Christensen et al.[19][20] and Green et al.[20]. Comorbidity group
weights, updated and validated by Quan et al.[21], ranging between 0 and 6 points for each
comorbidity group in the CCI were used. The NPR has used International Classification of
Disease (ICD)-8 codes during 1977–1993 and ICD-10 codes since 1994. All diagnoses were
coded to last for 10 years after date of diagnosis and then expire. For each day during follow-
up and for each comorbidity group, we checked if new valid diagnoses were registered. If so,
the weight of the comorbidity group to which the new diagnosis belonged was added to the
total CCI for the patient in question from date of diagnosis and 10 years onwards.
MC score, CCI, and the number of times entering the state in question varied within each
person during follow-up. Similar to age and duration of diabetes, we used the current value of
the scores at the time of the left endpoints of the follow-up intervals.
Calculations and statistical analyses
Implementation was calculated as the proportion of days with sufficient supply while being
persistent[18]. It is inherent in the algorithm that the size of the implementation degree
depends on both the maximum acceptable length of a supply gap and the prescribed amount
of medicine, which at Steno is typically 3 months at a time. Persistence was calculated as the
proportion of days in persistence of all days prescribed with the medicine in question.
Rate-ratios of incidence of the different events representing the different behavioural ele-
ments of adherence to medication over time were analysed through Poisson regression, where
the follow-up time for each individual was split in intervals of 3 months, and one record for
each time interval entered the Poisson model.
For the five time-varying covariates
1. age,
2. duration of T2DM diagnosis,
3. the Medication Complexity score (MC score): the number of medicines prescribed at any
time during follow-up as an indicator of polypharmacy,
4. Charlson’s Comorbidity Index (CCI),
5. number of times the patient has entered the state in question,
we used the current value of the covariates at the time of the left endpoints of the follow-up
time intervals. Thus, age and duration of T2DM diagnosis increased by 3 months for each fol-
low-up time interval related to the same individual.
The Poisson regression models rates of each of the events, i.e. incidence of initiation of ther-
apy, incidence of changing state from supply of medication to medication gap, incidence of
changing state from medication gap to supply of medication, and incidence of discontinuation
of medication treatment.
For the categorical variable “country of origin”, the incidence rate for individuals of Danish
origin was used as reference to produce incidence rate-ratios between individuals of Turkish/
Pakistani origin compared to individuals of Danish origin.
The effects of current age and duration of diabetes were entered as linear on the log-rate
scale in order to have a parsimonious representation of the effect of these variables. For the
four continuous covariates (age, diabetes duration, MC score, number of transitions out of
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state) we report the incidence rate-ratio by an increase of five years of age, of five years of dia-
betes duration, of 1 in MC score and of 1 in no. of transitions out of state, respectively. Thus all
estimates for each transition rates are derived from the same Poisson model.
Calculations and analyses were performed using SAS, version 9.3 (SAS Institute Inc., Cary,
NC, USA). Graphs were done in R, version 3.0.2 (http://www.R-project.org/).
Ethics statement and regulatory approvals
Access to and use of data have been granted by the Danish Data Protection Agency (J.no.
2009-41-3056 and 2014-41-2819) and The Danish Health and Medicines Authority (J.no. 7-
505-29-1553/1). All linked data was anonymised before being made available to us by Statistics
Denmark. Written consent from patients was not needed.
Results
A total of 5,232 patients (58% men) included in the study had been prescribed with 107 differ-
ent medicines from the following ATC classes: blood glucose lowering medicine, excluding
insulins (A10B), acetylsalicylic acid (B01AC06), antihypertensives (C02), diuretics (C03AB),
beta blocking agents (C07), calcium channel blockers (C08), agents acting on the renin-angio-
tensin system (C09), and lipid modifying agents (C10). Thirteen medicines were prescribed to
more than 500 patients [Table 1].
For analyses in this study, metformin (A10BA02), the frequently used groups of sulfonyl-
ureas (SUs) (A10BB), acetylsalicylic acid (B01AC06), thiazide diuretics in combination with
potassium (C03AB), angiotensin receptor blockers (ARBs) and angiotensin converting
enzyme inhibitors (ACEs) (C09AA+C09CA), and statins (C10AA) were selected. Insulins
(A10A) were not included although they are often part of a rather complex blood glucose low-
ering medication regimen for T2DM [10,11]. As insulin doses are not always determined in
advance and also dependent on physical activity and food intake, calculation of an adherence
pattern for insulins is not possible.
With a median age of 59.5 years [IQR: 51.8–68.4] and a median DM duration of 6 years
[IQR: 2–11] at entry, the patient population was followed for a total of 22,862 person-years
(mean: 4.4 years [std: 4.1]). An additional 382 person-years spent in trials at Steno were cen-
sored. Patients were primarily of Danish origin. Patients of Turkish or Pakistani origin
Table 1. Use of 13 most commonly prescribed medicines.
Metformin—A10BA02 3.449 66%
Glibenclamide—A10BB01 567 11%
Glimepiride—A10BB12 1.489 28%
Acetylsalicylic acid—B01AC06 3.856 74%
Bendroflumethiazide C03AB01 1.714 33%
Furosemide—C03CA01 1.627 31%
Metoprolol—C07AB02 1.004 19%
Amlopidine—C08CA01 1.588 30%
Enalapril—C09AA02 1.583 30%
Losartan—C09CA01 534 10%
Irbesartan—C09CA04 1.210 23%
Simvastatin—C10AA01 3.469 66%
Atorvastatin—C10AA05 746 14%
Number of patients (% of all 5,232 patients).
https://doi.org/10.1371/journal.pone.0179546.t001
Long-term patterns of adherence to medication therapy
PLOS ONE | https://doi.org/10.1371/journal.pone.0179546 June 30, 2017 5 / 15
constituted the other two largest groups (3% + 3%). One in five had achieved tertiary level
education and above, one third upper secondary, and one third lower secondary education,
with a higher proportion of men at upper secondary and tertiary level. The men also surpassed
the women’s annual income by €9,570. Two thirds of the patients were married, and of the
remaining there were more widows than widowers. The majority of patients had prescriptions
of two medicines or less at entry [Table 2]. At entry more than 88% had a CCI of either 0 or 1
[Table 2], indicating that less than two medical conditions existed simultaneously.
Fig 1 shows unadjusted variations in the adherence pattern between the 6 selected medicine
groups. During the first year of follow-up the proportion of patients not having initiated treat-
ment varied from 12.7% [95%CI: 11.5–13.9%] for sulfonylureas to 35.3% [95%CI: 34.2–36.5%]
for thiazide diuretics (blue + purple areas in Fig 1). The highest proportion of patients with
sufficient supply (green area in Fig 1) during the first five years was seen for metformin (77.4%
[95%CI: 77.2–77.6%]) and SUs (77.7% [95%CI: 77.5–78.0%]) and the lowest for thiazide
diuretics (53.7% [95%CI: 53.6–54.0]). Once in treatment, the degree of implementation (the
proportion of the combined green and orange areas being green in Fig 1) during years 2–5 was
stable at a level around 89.5% [95%CI: 89.5–89.6%] for metformin to 94.4% [95%CI: 94.3–
94.4%] for acetylsalicylic acid. During years 2 to 5 after the first prescription of medicine the
proportion of patients having discontinued treatment (red area in Fig 1) were 5.0% [95%CI:
4.9–5.0%] for statins to 7.7% [95%CI: 7.6–7.8%] for thiazide diuretics.
Age
Younger age was associated with poorer adherence, as it was associated with gaps of supply
(for metformin, SUs, and acetylsalicylic acid) [Fig 2B1]. Resuming supply of medicine after a
supply gap was positively associated with older age for metformin, SUs, acetylsalicylic acid,
and statins [Fig 2B2]. Furthermore, younger age was associated with discontinuation of met-
formin, SUs, and acetylsalicylic acid [Fig 2C].
Duration of diabetes mellitus
Longer diabetes duration was significantly associated with lower incidence of initiation of met-
formin, acetylsalicylic acid, ACEs & ARBs, and statins [Fig 2A], whereas diabetes duration was
inversely associated with running out of supply to a supply gap (for metformin and SUs) [Fig
2B1], indicating equivocal direction of the association between duration of diabetes and the
different phases of adherence to medication.
Country of origin
Turkish origin was positively associated with risk of supply gaps for SUs and acetylsalicylic
acid [Fig 2B1]. Pakistani origin (all medicine groups except SUs) and Turkish origin (all medi-
cine groups) were inversely associated with resuming supply of medicine after a supply gap
[Fig 2B2]. Pakistani origin (for metformin and thiazide diuretics) and Turkish origin (all medi-
cine groups except for ACEs and ARBs) were associated with discontinuation [Fig 2C]. Thus,
all significant results were unequivocal towards an association between Pakistani/Turkish ori-
gin and poorer adherence compared to patients of Danish origin.
Medication Complexity score
Higher MC score (a proxy for polypharmacy) was significantly associated with lower incidence
of initiation for all medicine groups except thiazide diuretics [Fig 2A] thus impacting adher-
ence negatively. But at the same time the MC score was negatively associated with running out
Long-term patterns of adherence to medication therapy
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Table 2. Baseline characteristics.
At entry: Men Women All
N 3.014 2.218 5.232
(%) 58% 42% 100%
Age, years (median) 59,5 61,2 60,0
[IQR] [51.7–66.9] [52.1–70.5] [51.8–68.4]
DM duration, years (median) 6 6 6
[IQR] [1–11] [2–12] [2–11]
Date of entry (median) Oct.2002 Aug.2002 Oct.2002
[IQR] [Jul.99 - Dec.05] [Mar.99 - Jan.06] [May.99 - Jan.06]
Country of origin 100% 100% 100%
Denmark 85% 81% 83%
Turkey 3% 4% 3%
Pakistan 3% 4% 3%
Other 9% 10% 10%
Unknown 1% 1% 1%
Education 100% 100% 100%
Lower secondary 30% 41% 35%
Upper secondary 43% 32% 38%
Tertiary and above 21% 15% 18%
Unknown 6% 12% 9%
Marital status 100% 100% 100%
Unmarried 15% 12% 14%
Married 66% 55% 62%
Divorced 13% 16% 15%
Widow/Widower 4% 14% 8%
Unknown 2% 2% 2%
Annual income, € (median) 30.483 20.913 24.979
[IQR] [18,750–46,427] [15,140–30,181] [16,958–39,342]
MC score a, median 1 1 1
[IQR] [0–3] [0–3] [0–3]
0 39% 40% 39%
1 19% 19% 19%
2 15% 14% 14%
3 9% 10% 10%
4 7% 7% 7%
> = 5 11% 10% 11%
Total 100% 100% 100%
CCI 0 0 0
(Continued)
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of supply to a supply gap (all medicine groups except statins) [Fig 2B1], as well as being nega-
tively associated with discontinuation (all medicine groups except statins) [Fig 2C].
Number of transitions out of a state
The number of times spent in a state of being with supply of ACEs and ARBs was positively
associated with running out of supply to a supply gap, meaning the more times a patient has
been in and out of supply (e.g. experiencing a repeated outage of medication supply), the more
likely the patient will run out of supply again [Fig 2B1]. Conversely, the number of times spent
in a state of a gap for metformin and acetylsalicylic acid was inversely associated with resuming
supply of medicine after a supply gap [Fig 2B2].
Results across initiation, implementation and discontinuation
There was a small, but insignificant trend that women were more adherent to medication ther-
apy than men (results not shown). Marital status, level of education, income, and burden of
comorbidities (CCI) were not associated with neither initiation, implementation nor discon-
tinuation of treatment (results not shown). An interaction between gender and being with or
without a partner (based on a hypothesis that single men have a different risk profile than sin-
gle women), was not significant (results not shown).
Discussion
Principal findings
The study showed that poor initiation, rather than poor implementation or discontinuation,
was the biggest contributor to overall nonadherence. Use of a multi-state model made it possi-
ble to distinguish between the three different elements of adherence. By investigating the
occurrence of four different behavioural events, our study adds to previous literature with this
clear distinction between initiation, implementation and discontinuation. This gives an insight
into the timing aspects of adherence that simple adherence rates or medication possession
rates cannot[11]. Thus, we have been able to add details to the associations between adherence
to medication and duration of diabetes and polypharmacy. Once the patients were in treat-
ment, polypharmcay was not associated with poorer implementation, and it was inversely
associated with early discontinuation, which to our knowledge are new findings.
Table 2. (Continued)
At entry: Men Women All
[IQR] [0–1] [0–1] [0–1]
0 60% 61% 60%
1 29% 26% 28%
2 6% 8% 7%
> = 3 5% 6% 5%
Total 100% 100% 100%
Follow-up time, years (mean) 4,3 4,4 4,4
(std) (4.0) (4.2) (4.2)
a MC Score: Medication Complexity score; CCI: Charlson’s Comorbidity Index.
https://doi.org/10.1371/journal.pone.0179546.t002
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Strengths and limitations
Attempts to generalise the results from this study to other diabetes cohorts should be done with
caution. It is estimated that approximately 20% of all T2DM patients in Denmark, primarily
complicated patients, are referred to tertiary care[22]. The Steno population is representative of
this group. The remaining approximately 80% are treated in primary care by general practition-
ers. It would be of interest to investigate if the primary care sector is able to achieve the same sta-
ble degree of persistence over time or if other patterns prevail. However, patients referred to
tertiary referral hospitals are a very important segment of T2DM patients with high risk of fur-
ther complications and a disproportionate high encumbrance on the health care system.
In Denmark the tax-funded nationwide healthcare system provides universal coverage to
all residents. Prescription drugs are paid for by the patient, but extensive reimbursement
Fig 1. Time course of adherence to metformin, sulfonylureas, acetylsalicylic acid, thiazide diuretics, ACEs & ARBs, and statins. Patients are
categorized in one of five different states during follow-up: Waiting and not having initiated treatment yet is represented by the blue area in the figure; having
filled prescriptions and having sufficient supply of medication to cover the daily prescribed dose (green area); being without supplies for a maximum of 50
days (yellow area); having discontinued treatment after a gap of 50 days without supplies of medication (red area), whereas the purple area represents
patients who do not initiate treatment by filling a prescription within the first 360 days and hence have not accepted the treatment. Patients will move between
the 5 states during follow-up according to their adherence behavior. The proportion of patients in each of the 5 states at any given time is shown on the
vertical axis. Further details are described by Jensen et al.[19].
https://doi.org/10.1371/journal.pone.0179546.g001
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options are available from the health authorities[23]. Income was not significantly associated
with adherence to medicine in our study. It is possible that some patients, not eligible for extra
individual reimbursement, were economically challenged, which might have reduced adher-
ence to medication therapy. It was not possible to investigate the effects of individual reim-
bursement in this study. Studies have found that there is no significant inequity in use of all
healthcare services in Denmark[24, 25]. But for services with co-payment, such as dental treat-
ment and medicine some inequity appears to be present, disfavouring the lower income
groups, immigrants and their descendants[24, 25]. Our study showed that supply gaps and dis-
continuing treatment were a bigger challenge for patients of Turkish/Pakistani origin com-
pared to patients of Danish origin.
It should be noted that the study design has an inherent risk of representing a “survivor
cohort” of patients retained in tertiary care over a longer period of time. This could partly
explain the absence of signals of inequity with regard to income. It also emphasizes the need
for analyses of the whole spectrum of T2DM patients.
Although not part of this study, analyses of adherence to insulins are also of high impor-
tance for this kind of study population. However, since calculations of adherence are chal-
lenged by frequent undetermined doses, and considerations of how to allow for waste of
insulin, analyses of insulins were not performed. A review by Davies et al.[26] has also men-
tioned the poor quality of studies on adherence to insulin therapy due to the use of non-vali-
dated tools.
This study is based on registries containing information on both prescribed medication
and what is actually filled, but without information from a Medication Event Monitoring
Fig 2. Rate-ratios for incidence of events of adherence to medication. Rate-ratios for Age (per 5 years), Diabetes duration (per 5 years),
Country of origin with Denmark as reference, Medication Complexity score (per 1 unit), and Number of transitions out of state (per 1 transition).
Panel A: For first initiation of treatment. For implementation: Panel B1: For running out of supply into a supply gap; Panel B2: For resuming supply
of medicine after a supply gap. Panel C: For first discontinuation of treatment. Panels A–D show rate-ratios for metformin, sulfonylureas,
acetylsalicylic acid, thiazide diuretics, ACEs & ARBs, and statins. DM, Diabetes Mellitus. MC score, Medication Complexity score. ACEs,
Angiotensin Converting Enzyme inhibitors. ARBs, Angiotensin Receptor Blockers.
https://doi.org/10.1371/journal.pone.0179546.g002
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System or similar pill count systems. This means we do not have information on which partic-
ular days the medicine is ingested if at all. Our data can tell when and how much medicine is
available to the patient, and has the advantage of covering 22,862 person-years of follow-up. It
would be an extremely comprehensive and expensive study if a daily pill count system were to
be used for such a long period of follow-up time including a substantial number of different
medicines.
Clinical parameters (e.g. blood pressure, HbA1c, or LDL cholesterol) from the patients were
not included in the modelling of the rates of adherence because the major impact of these are
most likely mediated through the prescription pattern already included in the model. We are
very well aware of the challenges of time-dependent confounding because prescription of med-
ication is dependent on previous measures of clinical parameters and a patient’s adherence to
the prescribed medication is, too. At the same time, future measures of clinical parameters are
dependent on previous patterns in prescription of medication and adherence to the prescribed
medication.
In line with our study, Karter et al.[27] have emphasised the need for more attention to
address nonpersistence in the very first stages after a new medicine is prescribed, which corre-
sponds to the relatively large proportion of patients waiting to initiate treatment during the
first year in our study. We were unable to investigate to which extent the period when patients
were waiting to initiate treatment[23, 28]could be attributed to a switch between two medi-
cines from the same class, where the patient was not to start the new medicine before any
stock of the old medicine had been used.
Time during any hospitalisations was not accounted for. Beloin-Jubinville et al.[29] have
found that hospitalisation did not appear to influence patient behaviour towards adherence to
medication therapy. The extent to which the patients have been supplied with medication
from a hospital during any hospitalization was not possible to determine.
Therapy related factors such as adverse effects, patient friendliness of regimen, dose-dis-
pensed medicines[30] (also known as multidose drug dispensing[31]) vs. traditional pill boxes
and blister packs, fixed-dose single-pill combinations[32], and taste of the medicines[33] were
not investigated.
Findings in relation to other studies
Gue´nette et al.[34] reported persistence and implementation to be associated with older ages
and a history of using 5 or more medicines, which supports our results. Lemstra et al.[16]
found immediate discontinuation after a single fill contributes disproportionately to statin
nonadherence in three Canadian cohorts. Hansen et al.[35] detected a large group of “early
quitters” (premature medication therapy discontinuation with 84 DDD during the first 6
months) in a study of antiosteoporotic therapy among 100,949 Danish men and women. Both
Blaschke et al.[12], from a database including 95 clinical studies, and Yeaw et al.[36], from a
pharmacy claims database, reported a large proportion of patients discontinuing treatment
within the first year. This picture of discontinuation is not seen in our study, perhaps due to
the setting of Steno as a tertiary referral hospital with frequent interactions between patient
and health care professionals, close monitoring of patients, and the before mentioned inherent
risk of a “survivor cohort”.
Conflicting results for diabetes treatment are found by Rolnick et al.[37]. They found higher
adherence in men and in those on fewer medicines (similar to our MC score). In a Danish
study by Wallach-Kildemoes et al.[38], adherence to preventive statin therapy decreased with
increasing income. The two Danish cohorts are probably not comparable (predominantly pri-
mary vs. tertiary care, and patients with no prior diabetes diagnosis vs. T2DM patients with an
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overrepresentation of patients with a high disease burden). In an Australian cohort of statin
users, Warren et al.[39] discovered a trend towards greater adherence (in terms of medication
possession ratio) with increasing age. Patients with a history of prior heart disease were more
likely to adhere to long-term use of statins. Language other than English was a major risk fac-
tor for non-adherence. If language barriers can be assumed to pose a challenge for a majority
of the Steno patients of Turkish/Pakistani origin, our findings on age and ethnicity are in line
with Warren’s.
The CCI was included in the analysis as a proxy for comorbidity. It did not show any associ-
ations with adherence to medication therapy. Diagnoses of depression are not included in
CCI. However, depression has independently been associated with lower adherence among
patients with chronic obstructive pulmonary disease[40] and in hypertensive patients[41].
Cross-sectional studies have shown associations between patients’ illness perception and
adherence to medication therapy[42–44]. Future studies of associations between comorbid
conditions and adherence to medication therapy may consider depression and patients’ illness
perceptions and beliefs.
A translation of the findings to clinical management of diabetes would focus on one major
element: An effort to support patients further when they are introduced to new drug combina-
tions/complex drug strategies should be prioritized since inertia was seen in initiating treat-
ment, and medication complexity (a proxy for polypharmacy) as well as duration of diabetes
were risk factors for poor initiation of treatment. The proportion of persistent patients was sta-
ble over time and there were no increase in supply gaps or discontinuation over time, which
further supports the view of prioritizing initiation of treatment. This should be seen in the con-
text of a tertiary care setting with frequent interactions between patient and health care profes-
sionals and a close monitoring of patients. Furthermore, intervention studies are needed to
test methods, particularly for improving initiation of further amendments to medication ther-
apy among patients already on a complex medicine regimen.
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